Floatz logo

Technetate(3-)-99Tc, (N-(4-(((2-Amino-1,4-Dihydro-4-Oxo-6-Pteridinyl)Methyl)Amino)Benzoyl)-D-.Gamma.-Glutamyl-(2S)-2-(Amino-.Kappa.N)-.Beta.-Alanyl-L-.Alpha.-Aspartyl-.Kappa.N-L-Cysteinato(6-)-.Kappa.N,.Kappa.S)Oxo-, Hydrogen (1:3), (Sp-5-24)-

Systemic Lupus Erythematosus

Mayo ClinicSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

23 Active assets in the Systemic Lupus Erythematosus cohort.

Asset / SponsorPhaseRating
Dehydroepiandrosterone
National Center for Research Resources (NCRR)
Phase 3BB
Rivaroxaban
University College, London
Phase 2B
Warfarin
University College, London
Phase 2B
Cytarabine
National Center for Research Resources (NCRR)
Phase 2B
Moderna Covid-19 Vaccine Rna
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2CCC

View all 34 →

Same molecule, other indications

Technetate(3-)-99Tc, (N-(4-(((2-Amino-1,4-Dihydro-4-Oxo-6-Pteridinyl)Methyl)Amino)Benzoyl)-D-.Gamma.-Glutamyl-(2S)-2-(Amino-.Kappa.N)-.Beta.-Alanyl-L-.Alpha.-Aspartyl-.Kappa.N-L-Cysteinato(6-)-.Kappa.N,.Kappa.S)Oxo-, Hydrogen (1:3), (Sp-5-24)- is also rated in:

rheumatoid arthritisDormant
B
Indicative · Phase 2
57 / 100
View asset →
osteoarthritisDormant
B
Indicative · Phase 2
57 / 100
View asset →
Crohn diseaseDormant
B
Indicative · Phase 2
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →